Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : RA Capital Management
Deal Size : $14.0 million
Deal Type : Financing
Pahr Therapeutics Raises $14 Million Seed Financing for PAH
Details : The company will use the proceeds to develop novel therapies for pulmonary arterial hypertension (PAH).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 28, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : RA Capital Management
Deal Size : $14.0 million
Deal Type : Financing